Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk

The vCJD safety of using UK-sourced plasma for the manufacture of five additional plasma derived medicinal products (Fibrinogen, Prothrombin Complex Concentrates (PCCs), C1 Esterase Inhibitor, Factor X and Protein C) was reviewed.Based on current epidemiology, manufacturing process capability, expert advice and information collected during previous reviews, it was concluded that UK-sourced plasma can be used for the manufacture of these five additional plasma derived medicinal products, in addition to the previously approved manufacture of immunoglobulins and albumins.